Evidence map›Paper›PMID 39825365›Full record

ArticleJournal of translational medicine2025

PRDX2 induces tumor immune evasion by modulating the HDAC3-Galectin-9 axis in lung adenocarcinoma cells.

Yunjia Dong, Anqi Cheng, Jiawei Zhou, Jianqiang Guo, Yafeng Liu, Xuan Li, Maoqian Chen, Dong Hu, Jing Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yunjia DongSchool of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Anqi Cheng *School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Jiawei ZhouSchool of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Jianqiang GuoSchool of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Yafeng LiuSchool of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Xuan LiSchool of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Maoqian ChenSchool of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China.
Dong HuThe First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital, School of Medicine), Huainan, Anhui, 232000, China. dhu@aust.edu.cn.
Jing WuJoint Research Center for Occupational Medicine and Health of IHM, School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, 232000, China. aust_jingwu@aust.edu.cn.

Funding

Cultivation Fund of the Key Scientific and Technical Innovation Project, Ministry of Education YZ2023H2A001National Defense Science and Technology Innovation Fund of the Chinese Academy of Sciences YZ2023H1A006the Research Funds of Joint Research Center for Occupational Medicine and Health of IHM OMH-2023-09
6 · The paper itself

Abstract

backgroundPRDX2 is significantly expressed in various cancers and is associated with the proliferation of tumor cells. Nonetheless, the precise mechanism of PRDX2 in tumor immunity remains incompletely understood. This study aims to investigate the impact of PRDX2, which is highly expressed in lung adenocarcinoma, on T cells in the tumor immune microenvironment, and its immune action target to promote the immune escape of lung cancer cells, to provide a theoretical basis for lung adenocarcinoma treatment with PRDX2 as the target.

methodsMouse animal models to verify the effect of Conoidin A treatment on tumor growth and T cell infiltration. Flow cytometry and Western blot verified tumor cell apoptosis in the in vitro co-culture system as well as granzyme B and perforin expression in T cells. RNA-Seq was used to obtain the downstream immune molecule. si-RNA knockdown of Galectin-9 was co-cultured with T cells in vitro. Immunofluorescence and Western blot verified that PRDX2 regulates Galectin-9 expression through HDAC3.

resultsPRDX2 expression was negatively correlated with CD8

conclusionsThis study reveals the role of the PRDX2/HDAC3/Galectin-9 axis in LUAD immune escape and indicates Galectin-9 as a promising target for immunotherapy.

Indexed as

Adenocarcinoma of LungGalectinsHistone DeacetylasesLung NeoplasmsPeroxiredoxinsTumor EscapeAnimalsApoptosisCD8-Positive T-LymphocytesCell Line, TumorFemaleGene Expression Regulation, NeoplasticHistone Deacetylase 3HumansMiceTumor MicroenvironmentGalectinsHistone Deacetylase 3Histone DeacetylasesPeroxiredoxinsPRDX2 protein, humanGalectin-9HDAC3Immune checkpointLung adenocarcinomaPRDX2

Identifiers

PMID39825365
PMCPMC11740609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.